Header Logo

Impact of COVID-19 on outcomes with teclistamab in patients with relapsed/refractory multiple myeloma in the phase 1/2 MajesTEC-1 study.

van de Donk NWCJ, Bahlis N, Costa LJ, Mateos MV, Nooka AK, Perrot A, Garfall AL, Thaman P, Qi K, Uhlar C, Chastain K, Doyle M, Usmani SZ. Impact of COVID-19 on outcomes with teclistamab in patients with relapsed/refractory multiple myeloma in the phase 1/2 MajesTEC-1 study. Blood Cancer J. 2024 Oct 21; 14(1):186.

View in: PubMed